<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611882</url>
  </required_header>
  <id_info>
    <org_study_id>15554</org_study_id>
    <secondary_id>NCI-2018-00037</secondary_id>
    <nct_id>NCT02611882</nct_id>
  </id_info>
  <brief_title>Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients</brief_title>
  <acronym>PSMA PET</acronym>
  <official_title>Evaluation of Gallium-68 HBED-CC-PSMA Imaging in Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Hope</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are imaging patients with prostate cancer using a new PET imaging agent&#xD;
      (Ga-68 HBED-CC PSMA) in order to evaluate it's ability to detection prostate cancer in&#xD;
      patients with high risk disease prior to prostatectomy, patients with biochemical recurrence&#xD;
      and patients with castrate resistant prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Imaging and staging of prostate cancer is critical for surgical and treatment planning.&#xD;
      Patients with suspected metastatic prostate cancer will be imaged using Gallium-68 labeled&#xD;
      HBED-CC PSMA in order to demonstrate its utility. The investigators plan to utilize this data&#xD;
      to obtain further approvals of the HBED-CC PSMA compound, so that this agent will become&#xD;
      available for clinical imaging in prostate cancer patients.&#xD;
&#xD;
      This compound has been shown to be superior to choline based PET agents for the staging of&#xD;
      prostate cancer, both Carbon-11 and Fluorine-18 compounds. But this compound was not patented&#xD;
      and therefore no company or private entity will make the investment required to bring HBED-CC&#xD;
      PSMA to market. In the vacuum of availability, academic groups must take the lead in order to&#xD;
      collect the necessary data for future FDA approval.&#xD;
&#xD;
      This study focuses on three patients populations that are imaged. In the pre-prostatectomy&#xD;
      population, the primary objective is to determine the sensitivity and specificity for&#xD;
      detection on nodal metastasis. In the biochemical recurrence population, the primary&#xD;
      objective is to determine the sensitivity of recurrence location. In the castrate resistant&#xD;
      prostate cancer population the primary objective is to determine if PSMA PET detects more&#xD;
      metastatic lesions than conventional imaging.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 18, 2015</start_date>
  <completion_date type="Actual">October 24, 2016</completion_date>
  <primary_completion_date type="Actual">October 24, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastases</measure>
    <time_frame>1 day</time_frame>
    <description>Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true positive rate will be calculated with the corresponding 95% confidence interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis</measure>
    <time_frame>1 day</time_frame>
    <description>Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true negative rate will be calculated with the corresponding 95% confidence interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Predictive Value (PPV) of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis</measure>
    <time_frame>1 day</time_frame>
    <description>Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true negative rate will be calculated with the corresponding 95% confidence interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative Predictive Value (NPV) of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis</measure>
    <time_frame>one month</time_frame>
    <description>Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true negative rate will be calculated with the corresponding 95% confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Detection Rates of Ga68-PSMA-11 by PSA Levels for the BCR Group</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>68Ga-labeled prostate-specific membrane antigen 11 (Ga68-PSMA-11) PET positivity rate by prostate-specific antigen (PSA) level is calculated by the number of positive reads divided by the total number of patients in the BCR Group per PSA value quintile (Detection rate (d) = total number of positive reads (t)/ total number of participants (N)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Biochemical Recurrence (BCR) Group Who Had a Reported Change in Medical Management</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Change in participant medical management was determined based on the results of surveys given to each participant's treating physician. Results of the survey were categorized as a major change in participant's medical management, a minor change in participant's medical management, no change to participant's medical management, or change to participant's medical management is unknown. These categories were developed based on a predetermined categorization schema.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>High-risk prostate cancer pre-prostatectomy (preRP) population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with high-risk prostate cancer pre-prostatectomy.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biochemical Recurrence (BCR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with prostate cancer with biochemical recurrence&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Castrate Resistant Prostate cancer (CRCP) population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with castrate resistant prostate cancer.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ga-68 labeled HBED-CC PSMA</intervention_name>
    <description>The imaging agent (Ga-68 HBED-CC PSMA) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET/CT imaging. The one-time nominal injected dose will be 3 to 7 millicurie (mCi) containing 10 - 25 Î¼g Ga-68 HBED-CC PSMA.</description>
    <arm_group_label>Biochemical Recurrence (BCR)</arm_group_label>
    <arm_group_label>Castrate Resistant Prostate cancer (CRCP) population</arm_group_label>
    <arm_group_label>High-risk prostate cancer pre-prostatectomy (preRP) population</arm_group_label>
    <other_name>Ga-68 labeled DKFZ-PSMA-11</other_name>
    <other_name>Ga-68 labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>Ga-68 labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT)</intervention_name>
    <description>Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/CT scan includes two parts: a PET scan and a CT scan. The CT portion of the scan produces a 3-D image that shows a patient's anatomy. The PET scan demonstrates function and what's occurring on a cellular level. The PET scan is unique because it images the radiation emitted from the patient while the CT records anatomical x-rays, showing the same area from another perspective</description>
    <arm_group_label>Biochemical Recurrence (BCR)</arm_group_label>
    <arm_group_label>Castrate Resistant Prostate cancer (CRCP) population</arm_group_label>
    <arm_group_label>High-risk prostate cancer pre-prostatectomy (preRP) population</arm_group_label>
    <other_name>PET/CT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)</intervention_name>
    <description>Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Coverage for the scan will extend from the patients vertex through the mid thighs. We will use 4 minute acquisitions per bed position for PET imaging.</description>
    <arm_group_label>Biochemical Recurrence (BCR)</arm_group_label>
    <arm_group_label>Castrate Resistant Prostate cancer (CRCP) population</arm_group_label>
    <arm_group_label>High-risk prostate cancer pre-prostatectomy (preRP) population</arm_group_label>
    <other_name>PET/MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Known prostate cancer with a clinical concern for the presence of metastatic disease&#xD;
             as delineated below:&#xD;
&#xD;
               -  Treatment naÃ¯ve patients with one of the following risk factors: CAPRA (Cancer of&#xD;
                  the Prostate Risk Assessment) score â¥ 5, Prostate-specific antigen (PSA) â¥ 15&#xD;
                  ng/mL and/or Gleason score â¥ 4+4.&#xD;
&#xD;
               -  Patients with biochemical recurrence after prostatectomy or radiation therapy&#xD;
                  with a PSA doubling time less than 12 months.&#xD;
&#xD;
                  i. These patients may have received androgen deprivation therapy prior to&#xD;
                  imaging.&#xD;
&#xD;
               -  Patients with castrate resistant prostate cancer with progressive disease as&#xD;
                  defined by Prostate Cancer Clinical Trials Working Group (PCWG2) criteria (27).&#xD;
&#xD;
                  i. Patients with castrate resistant prostate cancer can be either on treatment or&#xD;
                  off treatment&#xD;
&#xD;
          2. Age &gt; 18.&#xD;
&#xD;
          3. Karnofsky performance status of &gt; 50 (or Eastern Cooperative Oncology Group&#xD;
             (ECOG)/World Health Organization (WHO) equivalent).&#xD;
&#xD;
          4. Ability to understand a written informed consent document, and the willingness to sign&#xD;
             it.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients exceeding the weight limitations of the scanner or are not able to enter the&#xD;
             bore of the PET scanner due to BMI.&#xD;
&#xD;
          2. Inability to lie still for the entire imaging time (e.g. cough, severe arthritis,&#xD;
             etc.).&#xD;
&#xD;
          3. Inability to complete the needed investigational due to other reasons (severe&#xD;
             claustrophobia, radiation phobia, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Hope</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lawhn-Heath C, Flavell RR, Behr SC, Yohannan T, Greene KL, Feng F, Carroll PR, Hope TA. Single-Center Prospective Evaluation of (68)Ga-PSMA-11 PET in Biochemical Recurrence of Prostate Cancer. AJR Am J Roentgenol. 2019 Aug;213(2):266-274. doi: 10.2214/AJR.18.20699. Epub 2019 Apr 30.</citation>
    <PMID>31039025</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>November 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2015</study_first_posted>
  <results_first_submitted>November 3, 2020</results_first_submitted>
  <results_first_submitted_qc>November 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 22, 2020</results_first_posted>
  <disposition_first_submitted>April 6, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 10, 2018</disposition_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Thomas Hope</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through clinicians located at San Francisco Veteran's Affairs Medical Center and University of California, San Francisco Helen Diller Family Comprehensive Cancer Center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>High-risk Prostate Cancer Pre-prostatectomy (preRP) Population</title>
          <description>Patients with high-risk prostate cancer pre-prostatectomy.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
        </group>
        <group group_id="P2">
          <title>Biochemical Recurrence (BCR) Population</title>
          <description>Patients with prostate cancer with biochemical recurrence.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
        </group>
        <group group_id="P3">
          <title>Castrate Resistant Prostate Cancer (CRCP) Population</title>
          <description>Patients with castrate resistant prostate cancer. Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="150"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Surgery Per Protocol</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="150"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not complete prostatectomy per protocol stipulation</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>No participants were enrolled in the CRCP arm of this protocol</population>
      <group_list>
        <group group_id="B1">
          <title>High-risk Prostate Cancer Pre-prostatectomy (preRP) Population</title>
          <description>Patients with high-risk prostate cancer pre-prostatectomy.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
        </group>
        <group group_id="B2">
          <title>Biochemical Recurrence (BCR) Population</title>
          <description>Patients with prostate cancer with biochemical recurrence.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
        </group>
        <group group_id="B3">
          <title>Castrate Resistant Prostate Cancer (CRCP) Population</title>
          <description>Patients with castrate resistant prostate cancer.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="150"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="225"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>40-49 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90-99 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B4" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B4" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B4" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastases</title>
        <description>Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true positive rate will be calculated with the corresponding 95% confidence interval.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-risk Prostate Cancer Pre-prostatectomy (preRP) Population</title>
            <description>Patients with high-risk prostate cancer pre-prostatectomy.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
          </group>
          <group group_id="O2">
            <title>Biochemical Recurrence (BCR) Population</title>
            <description>Patients with prostate cancer with biochemical recurrence.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastases</title>
          <description>Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true positive rate will be calculated with the corresponding 95% confidence interval.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".59"/>
                    <measurement group_id="O2" value=".89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specificity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis</title>
        <description>Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true negative rate will be calculated with the corresponding 95% confidence interval.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-risk Prostate Cancer Pre-prostatectomy (preRP) Population</title>
            <description>Patients with high-risk prostate cancer pre-prostatectomy.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
          </group>
          <group group_id="O2">
            <title>Biochemical Recurrence (BCR) Population</title>
            <description>Patients with prostate cancer with biochemical recurrence.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis</title>
          <description>Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true negative rate will be calculated with the corresponding 95% confidence interval.</description>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".80"/>
                    <measurement group_id="O2" value=".31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Positive Predictive Value (PPV) of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis</title>
        <description>Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true negative rate will be calculated with the corresponding 95% confidence interval.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-risk Prostate Cancer Pre-prostatectomy (preRP) Population</title>
            <description>Patients with high-risk prostate cancer pre-prostatectomy.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
          </group>
          <group group_id="O2">
            <title>Biochemical Recurrence (BCR) Population</title>
            <description>Patients with prostate cancer with biochemical recurrence.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Predictive Value (PPV) of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis</title>
          <description>Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true negative rate will be calculated with the corresponding 95% confidence interval.</description>
          <units>proportion of true positives</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".67"/>
                    <measurement group_id="O2" value=".906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Negative Predictive Value (NPV) of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis</title>
        <description>Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true negative rate will be calculated with the corresponding 95% confidence interval.</description>
        <time_frame>one month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>High-risk Prostate Cancer Pre-prostatectomy (preRP) Population</title>
            <description>Patients with high-risk prostate cancer pre-prostatectomy.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
          </group>
          <group group_id="O2">
            <title>Biochemical Recurrence (BCR) Population</title>
            <description>Patients with prostate cancer with biochemical recurrence.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>Negative Predictive Value (NPV) of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis</title>
          <description>Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true negative rate will be calculated with the corresponding 95% confidence interval.</description>
          <units>proportion of true negatives</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".74"/>
                    <measurement group_id="O2" value=".24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Detection Rates of Ga68-PSMA-11 by PSA Levels for the BCR Group</title>
        <description>68Ga-labeled prostate-specific membrane antigen 11 (Ga68-PSMA-11) PET positivity rate by prostate-specific antigen (PSA) level is calculated by the number of positive reads divided by the total number of patients in the BCR Group per PSA value quintile (Detection rate (d) = total number of positive reads (t)/ total number of participants (N)).</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Six patients did not have an evaluable PSA value pre-imaging for this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Biochemical Recurrence (BCR) Population</title>
            <description>Patients with prostate cancer with biochemical recurrence.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Detection Rates of Ga68-PSMA-11 by PSA Levels for the BCR Group</title>
          <description>68Ga-labeled prostate-specific membrane antigen 11 (Ga68-PSMA-11) PET positivity rate by prostate-specific antigen (PSA) level is calculated by the number of positive reads divided by the total number of patients in the BCR Group per PSA value quintile (Detection rate (d) = total number of positive reads (t)/ total number of participants (N)).</description>
          <population>Six patients did not have an evaluable PSA value pre-imaging for this analysis</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;0.5 ng/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 to &lt; 1.0 ng/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.0 to &lt; 2.0 ng/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.0 to &lt; 5.0 ng/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=5.0 ng/dl</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Biochemical Recurrence (BCR) Group Who Had a Reported Change in Medical Management</title>
        <description>Change in participant medical management was determined based on the results of surveys given to each participant's treating physician. Results of the survey were categorized as a major change in participant's medical management, a minor change in participant's medical management, no change to participant's medical management, or change to participant's medical management is unknown. These categories were developed based on a predetermined categorization schema.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Surveys for only 126 BCR participants were completed by their physicians</population>
        <group_list>
          <group group_id="O1">
            <title>Biochemical Recurrence (BCR) Population</title>
            <description>Patients with prostate cancer with biochemical recurrence.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Biochemical Recurrence (BCR) Group Who Had a Reported Change in Medical Management</title>
          <description>Change in participant medical management was determined based on the results of surveys given to each participant's treating physician. Results of the survey were categorized as a major change in participant's medical management, a minor change in participant's medical management, no change to participant's medical management, or change to participant's medical management is unknown. These categories were developed based on a predetermined categorization schema.</description>
          <population>Surveys for only 126 BCR participants were completed by their physicians</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to one year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High-risk Prostate Cancer Pre-prostatectomy (preRP) Population</title>
          <description>Patients with high-risk prostate cancer pre-prostatectomy.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
        </group>
        <group group_id="E2">
          <title>Biochemical Recurrence (BCR) Population</title>
          <description>Patients with prostate cancer with biochemical recurrence.&#xD;
Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Over one-half of the patients subsequently underwent radiation therapy and androgen deprivation therapy. In these patients PSA level almost universally falls to zero, and therefore no follow-up imaging is performed, effectively removing a large proportion of patients from our imaging follow-up.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Thomas Hope, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 221-4810 ext 2264</phone>
      <email>Thomas.Hope@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

